Effectiveness and Outcomes of Ceftazidime -Avibactam in the Treatment of Infections due to Carbapenem-Resistant Klebsiella Pneumoniae.

In the intensive care units (ICUs), gram-negative sepsis has proven to be amongst the most difficult to treat infections. This retrospective study was conducted to examine the efficacy of ceftazidime-avibactam (CAZ-AVI) in patients with infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-KP) in a Delhi hospital. We aimed to evaluate the clinical treatment success rate in patients treated with CAZ-AVI on day 14 or at the end of treatment (EOT), whichever was earlier. Data from 100 patients was analysed. The 14-day survival rate with CAZ-AVI was 55% and the 30-day survival rate was 52%, as 3 patients died between days 15 and 30. All surviving patients showed clinical improvement. Microbiological outcomes were available for 44 cases, of whom 38 (86.4%) were positive and 6 were negative. The mortality was lower in the negative cases, but was not statistically significant (p = 0.807). The CAZ-AVI success rate in our study was high with more than half of the patients surviving at the end of both the 14th and 30th day.